The global prostaglandin E receptor EP subtype market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The prostaglandin E receptor EP is a member of the G-protein coupled receptors. It binds to ligands such as Prostaglandin (PG)E, PGD, or PGF and plays a critical role in the modulation of inflammatory responses. The stimulation of this receptor results in inflammation while inhibition leads to anti-inflammatory effects on body tissues. The major factor attributable to the market growth includes the increasing recognition of these drugs for various medical indications coupled with the benefits they offer. For instance, the prostaglandin E receptor EP subtype therapeutics are used for treating allergies, chronic to acute pain, and even for breast cancer, lung cancer treatment. Thus, the growth in the number of patients suffering from chronic pain, lung cancer, and so on are driving growth of the global prostaglandin E receptor EP subtype market. 

The prevalence of several forms of allergies among the global population is further anticipated to provide a major boost to the market growth. The prostaglandin E receptor EP subtype drug alleviates allergy by reducing swelling and thus, by causing blood vessels to constrict. This inhibits white cells from leaking out into tissue where it produces histamine, an inflammatory molecule that triggers allergy symptoms such as sneezing, watery eyes, coughing, and shortness of breath.

Some key players operating in the market include Amgen Inc., Merck KGaA, and Santen Pharmaceutical Co., Ltd., among others. These players are eyeing on strengthening their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Application 

o By Deployment Model

o By End-User 

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  Amgen Inc., Merck KGaA, and Santen Pharmaceutical Co., Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Prostaglandin E Receptor EP Subtype Market Report by Segment

By Type

• EP1

• EP2

• EP3

• EP4

By Application

• Clinic

• Hospital

• Others

Global Prostaglandin E Receptor EP Subtype Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa